OUR MENTORS

PAUL ANDERSON
Managing Director,
Orthocell Pty Ltd

SIMON HANDFORD
Manager, Office of Research Commercialisation,
​University of Western Australia

Martin is a radiologist and nuclear medicine specialist, with 30 years medical imaging experience and has been a partner of Perth Radiological Clinic since 1997 and Chairman since 2009. He is a non-executive director of ASX listed Resonance Health since 2007 and Chairman since 2012. He has an MBA from Melbourne University and is a Fellow of the Australian Institute of Company Directors.

He has been investing in start-ups and early stage companies since 2006 and has been a member of Perth Angels since 2012. He invests in approximately one new venture per annum across a broad range of industries.
.
 
​​Simon joined UWA in 2002 following research and project management positions in the agrochemical and pharmaceutical industries. A lapsed natural products microbiologist, he still enjoys exploring and developing business opportunities from academic research and helping researchers translate their findings.

Simon has a degree in biological sciences, is a Registered Technology Transfer Professional and manages UWA’s Research Commercialisation team.
 
Paul has over 16 years experience in the medical device and cellular therapeutic fields with expertise in bridging the gap between research and clinical practice in the development of emerging medical technologies. This encompasses applying the regulatory framework to the product and the accompanying ‘grey area’ interpretation, rebating pathways, marketing, sales, developing orthopaedic relationships, strategic and financial planning. Paul has a strong track record with his previous board position with Verigen Australia Pty Ltd, a human cell therapies company.
 
ANTHEA DOWNS
Regulatory Affairs Consultant

JULIE EMERY
Director,
Archer Emery & Associates

LIZ JENVEY​
Director,
Symbios Pty Ltd

Anthea is a regulatory affairs consultant with clients in Australia and the United States in various stages of registration of drugs and medical devices. She works with companies to develop  products and quality management systems to attain regulatory compliance.

Anthea completed her undergraduate degree in Sydney and worked in endocrinology research at Royal Prince Alfred Hospital. She has since worked for CellTech in the UK, PathWest, the Therapeutic Goods Administration, Admedus and Pfizer Perth. 

She has been running her own regulatory affairs consulting company for 3 years. She works with the Marshall Centre at UWA on a number ofl projects, and is a member of the TGA External Scientific Evaluation Panel.
 
Julie co-founded Archer Emery & Associates in 2006 after a ten year career at the Therapeutic Goods Administration. She has provided advice and regulatory and technical services to over 400 clients in the pharmaceutical, medical device, IVD medical device, cosmetics and food industries and prepared many successful product applications for products in these categories.

Julie has extensive technical and managerial experience as a regulator at the TGA, and in research and development of food and therapeutics.  She has also worked in the food industry and as a research scientist in medical device development.  She holds tertiary degrees in Science (Honours in Microbiology) and Law, and a Graduate Diploma of Business Administration (Technology Management).
Liz Jenvey moved to Perth from the UK in 1993 after 12 years in the international pharmaceutical development  industry, where she was the regulatory adviser on multi discipline pharmaceutical development project teams and was involved in worldwide  registration.  In her current role as a director at regulatory consultancy Symbios Pty Ltd, Liz  has worked with a wide range of clients, providing regulatory advice on all classes of medicines, devices and interface products such as cosmetics and food. 

Liz's expertise is predominantly Australian and European regulations. She has a science degree and a post graduate Diploma in Regulatory Affairs from the University of Wales College of Cardiff.  
DR JANET PREUSS
Managing Director,
QRC Solutions
AMANDA TIRTADINATA
Government Grants & Tax Incentives Specialist, EY Perth

BRIAN LEEDMAN​
Co-Founder,
​ResApp Health Ltd

​​Janet  is an entrepreneur with a blend of skills and experience, combining a scientific research background with business and company director training. She has a keen interest in the commercialisation of technology, particularly in the biotechnology sector, and has experience working in academia, government and private, public and not‑for‑profit organisations and at various levels, including at a Board and executive management level.

Janet’s qualifications include a PhD in Pharmacology, and business qualifications obtained through an MBA (Advanced).  She is also a graduate of the Australian Institute of Company Director’s Corporate Governance course. She has founded two companies that provide services to the biotechnology/life sciences industry. 
 
Amanda has over 12 years of professional experience assisting organisations and companies to obtain various government grants and incentives. Part of this role includes ensuring the correct company structure to allow the incentives to be claimed. Serving a diverse client base, Amanda has worked with companies ranging from start-ups to large multinationals, across various sectors including biotechnology, pharmaceutical, medical device, IT and technology, mining, and oil and gas. Amanda has background in biochemistry and microbiology, and is passionate about keeping and funding WA talents and companies in the Health and Life Sciences space.

Amanda is also a local champion of EY’s Entrepreneur of the Year and its affiliated programs. These are global programs to highlight and celebrate the achievement of entrepreneurs. 
Brian is a marketing and investor relations professional with over 15 years experience in the biotechnology industry. He is the Chairman of NeuroScientific Limited and formerly; a Director of Alcidion Limited and Executive Director of ResApp Health Limited. Previously, he co-founded Oncosil Medical Limited and Imugene Limited. Brian also served for 10 years as Vice President, Investor Relations of pSivida Corp. which is listed on the ASX and NASDAQ. He is the former WA Chairman of AusBiotech, the association of biotechnology companies in Australia. 

Brian is a former 40Under40 Winner during his time as Group Marketing Manager at the Perth office of Ernst & Young and holds a Bachelor of Economics and a Master of Business Administration from the University of Western Australia.
DR MICHAEL CHALLENOR
Scientist and Entrepreneur
COSIMO SANTELLA
Technical Project Manager, Fastbrick Robotics

CETTINA RACCUIA
Innovation Capability Manager, RAC WA

Michael is a professional scientist with academic experience in chemistry, pre-clinical in vitro testing, molecular biology and industry experience in analytical science and engineering consulting. He has a PhD in Nanotechnology.

Michael is a graduate of the 2016 SPARK Co-Lab Design Course at which his team took out first prize and started fetal monitoring device company Iris Biomedical. 
 
Cosimo has twenty years of experience working in product development, specializing in electronic, software and firmware engineering to create products in the medical, automotive, domestic and Industrial fields. He has managed cutting edge product development projects where research has been a critical component of the project life-cycle; and brings together teams including research, design, manufacturing, risk, quality and regulatory to move a product from concept to reality.

With a broad technical understanding and diverse project management experience, he considers himself to be a technology generalist. Cosimo has acted as a mentor for SPARK Co-Lab since 2016, and is also takes part on the judging panel for the Incite Award at the WA Information Technology and Telecommunications Awards (WAiTTA).
Cettina is an experienced program and operations leader, having held senior program management and operational roles across the health, education and finance sectors, in a range of different organisations from government, to start-up and corporate. With a key focus and strength in turn-around and growth, Cettina has deployed a number of different projects, from product development to organisational transformation.  

A graduate of the Master of Business Leadership program at Curtin University, with a Bachelor of Arts and Honours in Psychology, Cettina hopes to apply her knowledge and professional expertise to create an impact, and help solve some of the world’s toughest problems. Cettina is also a graduate of the 2016 SPARK Co-Lab Design Course.
DR MICHAEL WINLO
CEO, Linear Clinical Research Ltd

DR RAMIZ BOULOS
CEO, Boulos & Cooper Pharmaceuticals Pty Ltd

TODD SHAND
Principal, Wrays Perth
Mike has served as CEO of Linear Clinical Research since April 2016.  In that time WA’s only dedicated early phase clinical research unit has grown significantly, earning a national Business Services Award in 2017. Prior to Linear, Michael was based in Silicon Valley as the health lead for Palantir Technologies.

Michael holds an Bachelor of Medicine and Bachelor of Surgery from the University of Western Australia as well as an MBA from Stanford University Graduate School of Business where he also completed the Stanford Biodesign Course. He has acted as a mentor and faculty for SPARK Co-Lab's various course offerings since 2016.
 
Ramiz is the Chief Executive Officer of Boulos & Cooper Pharmaceuticals and one of its founding Directors. During the last year, Dr Boulos has been a Research Associate at Flinders University in South Australia, working on a range of projects for the Centre of NanoScale and Technology. Prior to this role, Dr Boulos worked at the Centre for Strategic Nanofabrication at the University of Western Australia.

In late 2012, Dr Boulos acquired the rights to the intellectual property which forms the basis of the novel antimicrobials the company is seeking to commercialise. Ownership of these patents has resulted from Dr Boulos’ research on the discovery of this new class of non-toxic antimicrobials and antioxidants.
Todd is a Perth-based principal at ​Wrays, a national intellectual property firm with extensive expertise in pharmaceuticals and medical technologies.

Todd has worked with pharmaceutical patents for more than 20 years. Over that time, he has acted for innovators, generics and subsidisers; for start-ups, ASX-listed companies, multinationals and government. He has drafted and prosecuted patents that are listed on the USFDA Orange Book, and has litigated for multinational pharmaceutical companies at all stages of the product life cycle, including patents directed to the active compound, to dosage forms and to dosage regimes.
ADJ/PROF PAUL WATT
​Director, Telethon Kids Institute and Phylogica
A UWA graduate, Paul Watt completed his doctorate in Molecular Biology at Oxford University before taking up postdoctoral appointments at Harvard and Oxford. He was subsequently appointed Adjunct Professor at the University for Western Australia and is Associate Director, Research Strategy and Director of Research Services and Innovation at the Telethon Kids Institute, where he is head of the Drug Discovery Unit.

Professor Watt has published 57 peer reviewed scientific papers and is primary inventor on 25 patent applications, most of which have been granted in the US and Europe and other jurisdictions.

Professor Watt is focused on technology translation, having founded InfaMed Ltd., now owned by Avita Medical, which globally marketed drug delivery device he invented. He is also a non-executive director of Phylogica, a drug discovery company he founded to commercialise a novel, structure-rich class of peptide known as Phylomers. Phylogica has done discovery alliances with several large Pharmaceutical companies including Janssen, Medimmune, Pfizer and Roche/Genentech. Professor Watt has held various roles in public and private biotechnology companies, including CSO, CEO and non-executive director.